Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CIK Cells + Chemotherapy in Stage IB-IIIA NSCLC
NCT01533727Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2011
- Primary completion
- Dec 2017
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Aug 2011; status: withdrawn.
02
Drugs
unmodified CIK
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01533727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01533727.